Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Running

NANOBAC Antibody-guided design of multivalent nanoparticle vaccines against bacterial pathogens

Coordinator
Lunds Universitet, Sweden
Runs
1 September 2025 to 31 August 2030
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101200871

What the project is doing

In the project's own words, from its summary on CORDIS.

Vaccines are the most effective single measure to protect populations against infectious diseases without promoting antimicrobial resistance (AMR). In this proposal, I intend to harness the rapid developments in protein design and quantitative and structural mass spectrometry to i) enable detailed molecular characterization of circulating serum antibody repertories, ii) establish a generalizable framework for antibody-guided design of next-generation nanoparticle vaccines against bacteria and iii) use the developed nanoparticle vaccines to investigate structural properties of protective antibody responses required for immunity.

The planned work relies on identifying and producing protective antigen-specific monoclonal antibodies from immune individuals. These antibodies are used to structurally characterize conserved epitopes in their correct three-dimensional conformation. The structural information is then harnessed to design multivalent nanoparticle vaccine candidates. The planned work is focused on i) determining the optimal combination of epitopes that generates the highest level of protection using Streptococcus pyogenes as a model system, ii) determine the molecular properties of the circulating serum antibody response that mediates the protection and iii) modify the epitope design to target conserved structural motifs typically found within protein families to produce immunogens that confer cross-pathogen protection.

The work will be novel as it will for the first time, demonstrate the design of a protective vaccine candidate against a protein family associated with distinct bacterial pathogens and infections. The concept will be extendable to other protein families and bacterial pathogens to aid in the combat against AMR.

Topics

Who is involved

OrganisationCityCountryRole
Lunds UniversitetLundSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI